AMYE GROVES: Open Payments
NPI 1295030393 · BOAZ, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 38 payments from 15 companies in 2025. Trend: 2023 $1,253 · 2024 $1,020 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 5 | $107 |
| AstraZeneca Pharmaceuticals LP | 6 | $96 |
| Astellas Pharma US Inc | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Novo Nordisk Inc | 4 | $63 |
| Exact Sciences Corporation | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| ABBVIE INC. | 2 | $45 |
| PFIZER INC. | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $43 |
Products named: REXULTI, Veozah, Ozempic, FANAPT, AIRSUPRA, UBRELVY, ELIQUIS, TRELEGY ELLIPTA.
Industry payments across AL — which companies pay providers there.
